2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Directors’ Report continued REMUNERATION REPORT (AUDITED) (CONTINUED) Performance Rights holdings of key management personnel 48 2012 01 Jan 12 Balance No. Award date Performance Rights awarded during the year No. Non Executive Directors Addison, J.L 750,000 1-May 2011 - Clarke, D 350,000 1-May 2011 - James, S 350,000 1-May 2011 - Webb, S 350,000 1-May 2011 - Executive Directors Rosen, H 2,000,000 1-May 2011 - Ogru, E 2,000,000 1-May 2011 - Key Management Personnel Alsop, H - 21-Mar-2012 750,000 Gavin, P 1,000,000 3-Oct-2011 - Arnott, A 200,000 3-Oct-2011 - Butala, D 1,000,000 3-Oct-2011 - El-Tamimy, M 1,000,000 3-Oct-2011 - Rosen, J - 21-Mar-2012 700,000 Kyriakou, K 750,000 3-Oct-2011 (750,000) Moses, G - - - Totals 9,750,000 700,000 - 2011 01 Jan 11 Balance No. Award date Performance Rights awarded during the year No. Non Executive Directors Addison, J.L - 1-May 2011 750,000 Clarke, D - 1-May 2011 350,000 James, S - 1-May 2011 350,000 Webb, S - 1-May 2011 350,000 Executive Directors Rosen, H - 1-May 2011 2,000,000 Ogru, E - 1-May 2011 2,000,000 Key Management Personnel Banti, F - - - Gavin, P - 3-Oct-2011 1,000,000 Arnott, A - 3-Oct-2011 200,000 Butala, D - 3-Oct-2011 1,000,000 Harrison, K - 3-Oct-2011 500,000 Kyriakou, K - 3-Oct-2011 750,000 Libinaki, R - 3-Oct-2011 500,000 Totals - 9,750,000 - PHOSPHAGENICS ANNUAL REPORT 2012
Fair value per performance right at award date 31 Dec 12 Balance No. Not Vested No. % of Remuneration consisting of Performance rights $0.07 750,000 750,000 20.3% $0.07 350,000 350,000 13.9% $0.07 350,000 350,000 13.9% $0.07 350,000 350,000 13.9% $0.07 2,000,000 2,000,000 11.2% $0.07 2,000,000 2,000,000 11.3% $0.14 750,000 750,000 12.0% $0.07 1,000,000 1,000,000 11.5% $0.07 200,000 200,000 5.8% $0.07 1,000,000 1,000,000 12.1% $0.07 1,000,000 1,000,000 13.5% $0.14 700,000 700,000 18.4% $0.07 - - - - - - - 10,450,000 10,450,000 49 Fair value per performance right at award date 31 Dec 11 Balance No. Not Vested No. % of Remuneration consisting of Performance rights $0.07 750,000 750,000 20.1% $0.07 350,000 350,000 10.6% $0.07 350,000 350,000 10.6% $0.07 350,000 350,000 10.6% $0.07 2,000,000 2,000,000 7.9% $0.07 2,000,000 2,000,000 8.0% - - - - $0.07 1,000,000 1,000,000 3.5% $0.07 200,000 200,000 1.2% $0.07 1,000,000 1,000,000 3.4% $0.07 500,000 500,000 2.1% $0.07 750,000 750,000 2.9% $0.07 500,000 500,000 1.9% 9,750,000 9,750,000 DIRECTOR’S REPORT
Page 1 and 2: 20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4: highlights March... April... May...
Page 5 and 6: 03 Jonathan Addison Chairman & Inde
Page 7 and 8: COLLABORATIONS Strategic Collaborat
Page 9 and 10: The Phosphagenics Evolution THE STO
Page 11 and 12: “ We also reached agreement with
Page 13 and 14: Overview of our opioid development
Page 15 and 16: 13 is branded as Butrans or Norspan
Page 17 and 18: Personal Care ASHLAND INC (FORMERLY
Page 19 and 20: BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22: cellulite contour crème BioElixia
Page 23 and 24: Intellectual Property Title Countri
Page 25 and 26: 2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28: DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30: Senior Management DR PAUL GAVIN Chi
Page 31 and 32: Phosphagenics Limited ABN 32 056 48
Page 33 and 34: Directors’ Report Your directors
Page 35 and 36: Directors’ Report continued Looki
Page 37 and 38: Directors’ Report continued Commi
Page 39 and 40: Directors’ Report continued REMUN
Page 43 and 44: Directors’ Report continued Share
Page 45 and 46: Directors’ Report continued Share
Page 47 and 48: Exercise Price Expiry Date Net othe
Page 49: Exercise Price Expiry Date Net othe
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71 and 72: Notes to the consolidated fi nancia
Page 73 and 74: Application date of standard Impact
Page 101 and 102:
Notes to the consolidated fi nancia
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Independent Auditor’s Report 111
Page 115 and 116:
Additional Shareholder Information
Page 117 and 118:
Additional Shareholder Information
Page 119:
corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?